---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-24-000115"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:51:56.349682+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q3 revenue $3.28B, adj EPS $3.50 vs $3.38; lowers FY adj EPS midpoint $0.10

## Summary
- Revenue $3.28B (+7.4% YoY); diluted EPS from cont ops $2.00 vs $2.11; adj EPS $3.50 vs $3.38.
- FY 2024 adj EPS midpoint lowered $0.10 to $14.30-$14.70 on ~$0.15 weather hit; FCF $161.5M.
- Diagnostics revenue $2.55B (+8.9% YoY), base business organic 5.7%; Biopharma rev $737.7M (+2.6%).
- Announced acquisitions of Ballad Health outreach assets, Lab Works, and Naples lab mgmt; closed Invitae and BioReference Health purchases.
- Quarterly dividend $0.72/share declared, payable Dec 13, 2024 to holders of record Nov 26, 2024.

## SEC filing metadata
- accession: 0000920148-24-000115
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014824000115/0000920148-24-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014824000115/lh-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-24-000115
- JSON: https://secwatch.observer/filing/0000920148-24-000115.json
- Plain text: https://secwatch.observer/filing/0000920148-24-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.